Evidence map›Paper›PMID 38044413›Full record

ArticleAnnals of biomedical engineering2024

Treatment with PB125

K M Andrie, D R Palmer, O Wahl, S Bork, M Campbell, M A Walsh, J Sanford, R V Musci, Karyn L Hamilton, Kelly S Santangelo and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of biomedical engineering, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

K M AndrieDepartment of Microbiology, Immunology & Pathology, Colorado State University, 1619 Campus Delivery, Fort Collins, CO, 80523-1619, USA.
D R PalmerOrthopaedic Bioengineering Research Laboratory, Department of Mechanical Engineering, School of Biomedical Engineering, Colorado State University, Fort Collins, CO, USA.
O WahlOrthopaedic Bioengineering Research Laboratory, Department of Mechanical Engineering, School of Biomedical Engineering, Colorado State University, Fort Collins, CO, USA.
S BorkDepartment of Microbiology, Immunology & Pathology, Colorado State University, 1619 Campus Delivery, Fort Collins, CO, 80523-1619, USA.
M CampbellDepartment of Microbiology, Immunology & Pathology, Colorado State University, 1619 Campus Delivery, Fort Collins, CO, 80523-1619, USA.
M A WalshDepartment of Health and Exercise Science, Colorado State University, 1582 Campus Delivery, Fort Collins, CO, 80523-1582, USA.
J SanfordDepartment of Microbiology, Immunology & Pathology, Colorado State University, 1619 Campus Delivery, Fort Collins, CO, 80523-1619, USA.
R V MusciDepartment of Health and Exercise Science, Colorado State University, 1582 Campus Delivery, Fort Collins, CO, 80523-1582, USA.
Karyn L HamiltonDepartment of Health and Exercise Science, Colorado State University, 1582 Campus Delivery, Fort Collins, CO, 80523-1582, USA. Karyn.Hamilton@colostate.edu.ORCID http://orcid.org/0000-0002-6320-8824
Kelly S SantangeloDepartment of Microbiology, Immunology & Pathology, Colorado State University, 1619 Campus Delivery, Fort Collins, CO, 80523-1619, USA. Kelly.Santangelo@colostate.edu.ORCID http://orcid.org/0000-0002-2348-594X
Christian M PuttlitzOrthopaedic Bioengineering Research Laboratory, Department of Mechanical Engineering, School of Biomedical Engineering, Colorado State University, Fort Collins, CO, USA. Christian.Puttlitz@colostate.edu.ORCID http://orcid.org/0000-0002-1255-8867
Colorado State University · US

Funding

Dual treatment of sarcopenia and osteoarthritis with a Nrf2 activatorR21AG054713 · NIA · COLORADO STATE UNIVERSITY · PI HAMILTON, KARYN L, SANTANGELO, KELLY S · 2017 to 2018
$418k
NIA NIH HHS R21 AG054713
6 · The paper itself

Abstract

Nuclear factor-erythroid 2-related factor-2 (Nrf2) is a transcription factor that serves as a master regulator of anti-inflammatory agents, phase I xenobiotic, and phase II antioxidant enzymes, all of which provide a cytoprotective role during disease progression. We hypothesized that oral administration of a purported phytochemical Nrf2-activator, PB125

Indexed as

NF-E2-Related Factor 2OsteoarthritisAnimalsBone and BonesDisease Models, AnimalFemaleGuinea PigsMaleX-Ray MicrotomographyNF-E2-Related Factor 2Bone agingGuinea pigNuclear factor-erythroid 2-related factor-2 (Nrf2)OsteoarthritisPB125

Identifiers

PMID38044413
OpenAlexW4389283604

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.